[{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$330.0 million","newsHeadline":"Sandoz completes acquisition of Aspen\u2019s Japanese operations, strengthening its position in world\u2019s third largest market for generics and off-patent medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Biological E","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Terminated Distribution and Commercialization Agreement of its SYMJEPI Products with Sandoz","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive NICE Recommendation for Rizmoic\u00ae (naldemedine) for OIC","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Ships First Medicine in Collaboration with Civica Rx to Supply Us Hospitals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Slayback Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Launches Generic Icatibant in U.S for Angioedema, Strategically Enhancing Injectables Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK to Sell Cephalosporin Antibiotics Business to Sandoz","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz in-Licenses Authorized Generic of Respiratory Medicine Proventil\u00ae HFA Inhalation Aerosol from Kindeva Drug Delivery","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Begins Phase III trial of Biosimilar Targeting Wet AMD Drug Eylea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Strengthens Pipeline by Entering Into Agreement for Biosimilar Bevacizumab, a Key Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Completes Acquisition of GSK\u2019s Cephalosporin Business, Reinforcing Leading Global Position in Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Submits Biologics License Application for Proposed Biosimilar Trastuzumab to US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Authorized Generic of Narcan\u00ae (Naloxone Hydrochloride) Nasal Spray 4 mg in US to Help Reverse Opioid Overdose, Expanding Access During Surge in Overdose Deaths","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Lenalidomide in 19 Countries Across Europe, Expanding Access to Essential Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Brimonidine Tartrate\/timolol Maleate Eyedrop in Us for Patients With Ocular Hypertension, Expanding Leading Ophthalmic Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches First Generic Pirfenidone in US for Patients With Idiopathic Pulmonary Fibrosis, Growing Its Respiratory Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Application for Proposed Biosimilar Adalimumab\u2019s High Concentration Formulation Accepted by EMA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Supplemental Biologics License Application Accepted by US FDA for Biosimilar Hyrimoz (adalimumab-adaz) High Concentration Formulation (HCF)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics Announces EMA Acceptance of Marketing Authorization Application for Proposed Biosimilar Natalizumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Further Progress on its Biosimilar Pipeline, With Release of Positive Results For Denosumab Integrated Phase I\/III Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Mainbridge Health Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"N\/A","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"N\/A"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Alteogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen\u2019s Hybrozyme\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Announces Agreement to Acquire Leading Antifungal Agent Mycamine\u00ae From Astellas, Reinforcing Hospital Offering and Leading Anti-Infectives Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive Chmp Opinion for Citrate-Free High Concentration Formulation of Adalimumab Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Biologics License Application For Proposed Biosimilar Denosumab Accepted By US FDA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives US FDA Approval for Biosimilar Hyrimoz\u00ae (adalimumab-adaz) High-Concentration Formulation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives EC Approval For Hyrimoz High-concentration Formulation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Adalvo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz To Exclusively Commercialize Six Products In The Us, Reinforcing Global Leadership Position In Off-patent Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Just \u2013 Evotec Biologics","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"N\/A","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Technology","graph2":"N\/A"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Marketing Authorization Applications For Proposed Biosimilar Denosumab Accepted By EMA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration to Treat PAH Patients in US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive CHMP Opinion for Multiple Sclerosis Biosimilar Natalizumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive Results from Mylight Phase lll Study for Biosimilar Aflibercept","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives FDA Approval for Tyruko (natalizumab-sztn), First and Only FDA-Approved Biosimilar for Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$62.5 million","newsHeadline":"Sandoz Completes Acquisition of Leading Antifungal Agent Mycamine\u00ae from Astellas, Reinforcing Leading Global Anti-Infectives Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive CHMP Opinion for Breast and Gastric Cancer Biosimilar Trastuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives European Commission Approval for Tyruko\u00ae (natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Executes Sandoz Spin-off, Completing Strategic Transformation into a Leading, Focused Innovative Medicines Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Confirms Sandoz Spin-off for October 4, 2023","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed\u00ae PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz launches First and Only Biosimilar for Multiple Sclerosis, Tyruko\u00ae (Natalizumab), in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$99.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Two Significant Agreements with Sandoz for China and Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Biocon Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$170.0 million","newsHeadline":"Sandoz Acquires Cimerli\u00ae Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$170.0 million","newsHeadline":"Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives FDA Approval for First and Only Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Hyrimoz\u00ae (adalimumab) High-Concentration Formulation in Europe, Aiming to Improve Patient Care","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Gains European Commission Approval For PYZCHIVA\u2122 a Biosimilar to Stelara (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Rymti Biosimilar Etanercept in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves biosimilar Pyzchiva\u00ae (ustekinumab-ttwe), to be commercialized by Sandoz in US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Gets EU Approval for Wyost\u00ae and Jubbonti\u00ae Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Sandoz B2B
Pyzchiva (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.
Wyost (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is approved for patients with bone metastases from solid tumors.
Rymti (etanercept-biosimilar) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 years or older, psoriatic arthritis, ankylosing spondylitis & plaque psoriasis.
Pyzchiva (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.
Wyost (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is approved for patients with bone metastases from solid tumors.
Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.
The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar product utilized in the treatment of patients diagnosed with breast cancer or metastatic stomach cancer.
Tyruko (natalizumab-sztn - biosimilar) is a highly effective anti-α4 integrin monoclonal antibody. It is indicated for the treatment of relapsing-remitting forms of multiple sclerosis.
Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.
The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
